NASDAQ:LSTA Lisata Therapeutics Earnings Date & Estimates $1.06 +0.06 (+6.44%) Closing price 04:00 PM EasternExtended Trading$1.04 -0.02 (-1.98%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Lisata Therapeutics is estimated to report earnings on Thursday, November 5, 2026, before market opens. Research:ProfileEarnings HistoryForecast Upcoming Earnings Announcement Announcement DateNovember 5, 2026TimeBefore Market Opens Add to CalendarGoogle Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab) What Analysts Expect from Lisata TherapeuticsLisata Therapeutics is expected to post earnings of -$1.1250 per share on revenue of $659 thousand. In the same quarter a year earlier Lisata Therapeutics reported -$0.49 per share. Lisata Therapeutics has beaten the consensus EPS estimate in 7 of its last 8 quarters.Consensus EstimatesConsensus EPS-$1.1250Expected Revenue$659 thousandPrior-Year EPS-$0.49Recent Track RecordLast ReportedQ2 2026Last Quarter EPS-$0.32EPS Beat Rate7 of last 8 quartersPrepare for the Earnings CallEarnings HistoryCompany ProfileQ2 2026 Earnings ReportQ1 2026 Earnings ReportQ4 2025 Earnings Report Lisata Therapeutics Earnings FAQ When does Lisata Therapeutics report earnings? Lisata Therapeutics (NASDAQ:LSTA) is estimated to report earnings on Thursday, November 5, 2026, before market opens. This date is estimated from past reporting schedules and may change once the company confirms it. What is the consensus EPS estimate for Lisata Therapeutics? Analysts expect Lisata Therapeutics to post earnings of -$1.1250 per share for the quarter. How much revenue is Lisata Therapeutics expected to report? The consensus revenue estimate for Lisata Therapeutics is $659 thousand for the quarter. Lisata Therapeutics Earnings HeadlinesLisata adds biopharma finance veteran Jeffrey Farrow to boardOctober 15, 2026 | proactiveinvestors.comLisata Therapeutics, Inc. Announces Appointment of Jeffrey Farrow as Class III Director and Audit Committee Member, Effective October 13, 2026October 14, 2026 | marketscreener.comMLast call for your free 0DTE reportThe 0DTE Game Plan lays out a simple 3-step framework for trading same-day options: Plan it, profit from it, protect it. This report normally sells for 29.97, but it's available as a free download for a limited time.October 26 at 1:00 AM | Profits Run (Ad)Lisata Therapeutics Expands Board, Appoints Independent DirectorOctober 14, 2026 | tipranks.comLisata Therapeutics Appoints Jeff Farrow to Board of DirectorsOctober 14, 2026 | globenewswire.comLisata Therapeutics wins new US patent for pancreatic cancer drugOctober 8, 2026 | proactiveinvestors.comSee More Lisata Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Lisata Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Lisata Therapeutics and other key companies, straight to your email. Email Address About Lisata TherapeuticsLisata Therapeutics (NASDAQ:LSTA) is a clinical-stage biotechnology company focused on developing therapies for solid tumors. The company’s approach is designed to improve the delivery and effectiveness of cancer treatments by targeting the tumor microenvironment, which can limit the penetration of medicines into tumors. Lisata’s lead investigational product is certepetide, formerly known as CEND-1. Certepetide is a tumor-penetrating peptide intended to selectively home to tumor tissue and temporarily modify the tumor microenvironment, potentially helping co-administered anticancer therapies reach cancer cells more effectively. The company is evaluating the therapy in combination with established cancer treatments across several solid-tumor indications. The company was previously known as Cend Therapeutics and adopted the Lisata Therapeutics name in 2022. Lisata is headquartered in San Diego, California, and conducts its research and clinical development activities through collaborations and clinical studies in the United States and other regions. The company is led by President and Chief Executive Officer David J. Mazzo, Ph.D.View Lisata Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Anthropic's IPO Filing Reveals a Massive Opportunity for AI Infrastructure GiantsBristol Myers Squibb's Cancer Breakthrough Could Have Implications Beyond Its Own StockBuy the Dip: 4 Stocks the Market Marked Down Too Far Ahead of Big CatalystsComfort Systems Earnings: AI Slowdown or More Growth Ahead?MarketBeat Week in Review – 10/19 - 10/23Amex Stock Slides on Job Cuts, But the Real Story Is MacroBloom Energy Just Reported—Its Biggest Order Is Still Waiting on a Pipeline Upcoming Earnings Hilton Worldwide (10/27/2026)Royal Caribbean Cruises (10/27/2026)CocaCola (10/27/2026)Baker Hughes (10/27/2026)ONEOK (10/27/2026)Robinhood Markets (10/27/2026)HSBC (10/27/2026)S&P Global (10/27/2026)Visa (10/27/2026)HCA Healthcare (10/27/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
